Cypherpunk Technologies (FRA:5MC) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5MC Cypherpunk Technologies Inc FRA:5MC
40 GF Score
Price €0.50
GF Value €3.28
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cypherpunk Technologies FFO per Share?

FFO per Share only applies to REITs.

FRA:5MC
40GF Score
Cypherpunk Technologies Inc FRA:5MC
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cypherpunk Technologies (FRA:5MC) Overvalued in 2026?

Based on GuruFocus' analysis, Cypherpunk Technologies stock appears to be undervalued. The current stock price of €0.50 is trading 84.7% below its estimated GF Value™ of €3.28. GuruFocus considers Cypherpunk Technologies to be Possible Value Trap.

Key valuation signals for FRA:5MC:

  • FFO per Share:
  • GF Value™: €3.28 vs. price of €0.50 (84.7% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the FRA:5MC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cypherpunk Technologies Business Description

Other Exchanges CYPH:USA5MC:Germany
Address 47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
40GF Score

Get the complete analysis for FRA:5MC

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50
Price
€3.28
GF Value